Target intelligence / Profile preview

Platelet-activating factor receptor (PTAFR) (PTAFR)

Target
PTAFR
Molecular classification
G protein-coupled receptor, Rhodopsin-like GPCR, Receptor
01

Overview

The Platelet-activating factor receptor (PAFR) is a member of the G protein-coupled receptor (GPCR) superfamily, specifically the rhodopsin-like family, encoded by the PTAFR gene (UniProt: P25105). It is primarily activated by platelet-activating factor (PAF), a potent phospholipid mediator involved in a wide array of physiological and pathological processes, including platelet aggregation and inflammatory cell activation. Upon activation, PAFR triggers intracellular signaling pathways such as the activation of phospholipase C and the mobilization of calcium, which are critical for the immune response and vascular permeability (StatPearls: NBK557544). PAFR plays a significant role in the pathogenesis of asthma, anaphylaxis, and systemic inflammatory response syndrome, making it a key target for anti-inflammatory drug development. While several antagonists like lexipafant and rupatadine have been developed, clinical success has been varied, with some drugs showing efficacy in allergic rhinitis while others failed in acute systemic conditions like pancreatitis (DrugBank: DB04854). The receptor is also implicated in cancer progression, where it may promote tumor cell metastasis and angiogenesis.

Other names
PAF receptorPAFRPlatelet-activating factor receptor
02

Mechanism of action

Competitive antagonism of the platelet-activating factor receptor, preventing the binding of the phospholipid mediator PAF and subsequent downstream signaling.

03

Biological functions

Signal transductionImmune responsePlatelet aggregationInflammationBronchoconstrictionChemotaxisCalcium signaling
04

Disease associations

InflammationAsthmaAnaphylaxisCardiovascular diseaseSepsisCancerAllergic rhinitis
05

Safety considerations

Potential for altered immune responseHypotensionGastrointestinal distressLimited clinical efficacy in systemic inflammatory trials
06

Interacting drugs

6 more in the full profile.

07

Biomarkers

PAF plasma levelsPTAFR mRNA expression in leukocytesPlatelet aggregation response to PAF

Source types: Peer-reviewed publication. Sources are available to Gosset users. Log in to see them.

Beyond the preview

Go deeper on Platelet-activating factor receptor (PTAFR) (PTAFR).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Platelet-activating factor receptor (PTAFR) (PTAFR).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call